Advocacy intelligence hub — real-time data for patient organizations
⚡ Live Alerts
University of Kansas Medical Center — PHASE2
The Hospital for Sick Children
Anagram Therapeutics, Inc. — PHASE2
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Foundation grants
Copay cards
Travel grants
Foundation Grants7
PAN Foundation — Cystic fibrosis
PAN Foundation
Good Days — Cystic fibrosis
Good Days
Patient Services Inc — Cystic fibrosis
Patient Services Inc
NORD Patient Assistance — Cystic fibrosis
NORD Patient Assistance
Patient Advocate Foundation — Cystic fibrosis
Patient Advocate Foundation
The Assistance Fund — Cystic fibrosis
The Assistance Fund
HealthWell Foundation — Cystic fibrosis
HealthWell Foundation
Copay Assistance6
Pulmozyme
Genentech
Trikafta
Vertex Pharmaceuticals
Kalydeco
Vertex Pharmaceuticals
ORKAMBI
Vertex
Tobramycin Inhalation Solution Pak
Horizon
SYMDEKO
Vertex
Travel Grants8
BC Cystic Fibrosis Subsidy for Medications and Travel Program
Boston Children's Hospital Cystic Fibrosis Patient Resources
Cystic Fibrosis Center Patient Resources
Cystic Fibrosis Copay Assistance Program - The Assistance Fund
Gilead Support Path Patient Assistance Program
Gilead Sciences
Kitabis Copay Assistance
The Assistance Fund Cystic Fibrosis Copay Assistance Program
The Assistance Fund
Vanderbilt Specialty Pharmacy Financial Assistance
Vanderbilt Specialty Pharmacy
Trikafta
(elexacaftor/tezacaftor/ivacaftor)Orphan drugVertex Pharmaceuticals
12.1 Mechanism of Action Elexacaftor and tezacaftor bind to different sites on the CFTR protein and have an additive effect in facilitating the cellul...
ALYFTREK
(VANZACAFTOR, TEZACAFTOR, AND DEUTIVACAFTOR)standardVertex Pharmaceuticals Incorporated
Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]
12.1 Mechanism of Action Vanzacaftor and tezacaftor bind to different sites on the CFTR protein and have an additive effect in facilitating the cellul...
Kalydeco
(IVACAFTOR)Orphan drugVertex Pharmaceuticals Incorporated
SYMDEKO
(TEZACAFTOR AND IVACAFTOR)Orphan drugVertex Pharmaceuticals Incorporated
ORKAMBI
(LUMACAFTOR AND IVACAFTOR)Orphan drugVertex Pharmaceuticals Incorporated
ALYFTREK
(VANZACAFTOR, TEZACAFTOR, AND DEUTIVACAFTOR)standardVertex Pharmaceuticals Incorporated
Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]
12.1 Mechanism of Action Vanzacaftor and tezacaftor bind to different sites on the CFTR protein and have an additive effect in facilitating the cellul...
Acetylcysteine
(ACETYLCYSTEINE)Orphan drugstandardHospira, Inc.
FDA Approves ALYFTREK
ALYFTREK (DEUTIVACAFTOR) received FDA approval.
FDA Approves ORKAMBI
ORKAMBI (IVACAFTOR) received FDA approval.
FDA Approves KALYDECO
KALYDECO (IVACAFTOR) received FDA approval.
FDA Approves KALYDECO
KALYDECO (IVACAFTOR) received FDA approval.
FDA Approves ORKAMBI
ORKAMBI (IVACAFTOR) received FDA approval.
FDA Approves SYMDEKO (COPACKAGED)
SYMDEKO (COPACKAGED) (IVACAFTOR) received FDA approval.
Marcus A Mall, MD
Charité - Universitätsmedizin Berlin
📍 Berlin, State of Berlin
Matthias Salathe, MD
University of Kansas Medical Center
📍 Kansas City, Kansas
Sophie Gohy
Cliniques Universitaires Saint-Luc
📍 Brussels
Jessica Lee, MPH
University of Kansas Medical Center
📍 Kansas City, Kansas
Zackary I Cleveland, PhD
Penny New
📍 Cincinnati, Ohio
Deepika Polineni, MD, MPH
The Children's Hospital Alabama, University of Alabama at Birmingham
📍 Birmingham, Alabama